GENERALIZED MYASTHENIA GRAVIS

This study tests the long-term safety and effectiveness of zilucoplan, a daily injection, in people with generalized myasthenia gravis (gMG), a condition that causes muscle weakness. About 200 participants who completed a prior zilucoplan trial will receive the drug for an extend…

This study tests a drug called rozanolixizumab in 12 children aged 2 to 18 with moderate to severe generalized myasthenia gravis, a condition that causes muscle weakness. The goal is to see if the drug is safe and helps control symptoms. Participants receive injections, and resea…

This phase 3 trial tests whether ALXN1720 can improve daily living and muscle strength in adults with generalized myasthenia gravis who have specific antibodies. About 260 participants will receive either the drug or a placebo for 26 weeks. The study is active but no longer recru…

This study tests an experimental drug called CNP-106 in 54 adults aged 18-75 with generalized myasthenia gravis, a condition that causes muscle weakness. The goal is to check if the drug is safe and how it affects the immune system. Participants receive either CNP-106 or a placeb…

This phase 3 trial tests batoclimab, a drug that blocks certain antibodies, in 240 adults with generalized myasthenia gravis (gMG). The study measures if batoclimab improves daily activities and muscle strength compared to a placebo. Participants receive injections weekly or bi-w…

This study looks at the long-term safety of a daily injection called zilucoplan in children with a rare muscle-weakening disease called generalized myasthenia gravis. It includes up to 8 children who have already completed a previous study. The goal is to see if the drug remains …

This study looks at the long-term safety of a drug called rozanolixizumab in children aged 2 and older with generalized myasthenia gravis, a condition that causes muscle weakness. The drug is given in 6-week treatment cycles. The main goal is to track serious side effects and see…

This study looks at the long-term safety of efgartigimod in children with generalized myasthenia gravis, a disease that causes muscle weakness. The 12 participants are kids who already took part in earlier studies of this drug. They will continue to receive efgartigimod either th…

This study tests a drug called ravulizumab in 12 children aged 6 to 18 with generalized myasthenia gravis (gMG), a condition that causes muscle weakness. The goal is to see how the drug works in the body and if it helps control symptoms. Participants receive the drug through an I…

This study tests two experimental drugs, pozelimab and cemdisiran, alone or together, in 288 adults with generalized myasthenia gravis (gMG), a disease that causes muscle weakness and fatigue. The goal is to see if the drugs improve daily activities and muscle strength. Participa…

This study tests an investigational drug called efgartigimod, given intravenously, for adults with generalized myasthenia gravis (gMG) who do not have the typical acetylcholine receptor antibodies. The trial compares the drug to a placebo to see if it improves daily activities an…